Anti-Her2-C825 BsAb

Anti-Her2-C825 BsAb is a bispecific monoclonal antibody (BsAb) developed by researchers at Memorial Sloan Kettering Cancer Center for use in pretargeted radioimmunotherapy (PRIT). The antibody is engineered with dual specificity: one arm targets the Human Epidermal Growth Factor Receptor 2 (HER2), a protein overexpressed in various cancers including breast and ovarian carcinomas, while the second arm (C825) is a high-affinity single-chain variable fragment (scFv) that binds to DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid) metal chelates. In the PRIT strategy, the BsAb is administered first to saturate HER2 receptors on tumor cells. Following the clearance of unbound BsAb from the circulation, a small-molecule radiohapten (such as [225Ac]PrDOTA or [177Lu]DOTA-Bn) is administered. This radiohapten is rapidly captured by the C825 arm of the tumor-bound BsAb, allowing for high-dose radiation delivery to the tumor site with minimal systemic toxicity. Preclinical studies have demonstrated significant efficacy and histologic cures in murine xenograft models of HER2-positive epithelial ovarian carcinoma and breast cancer.

Other names

anti-HER2 x anti-DOTA bispecific antibodyanti-HER-2 x anti-DOTA bispecific antibodyanti-HER 2 x anti-DOTA bispecific antibody